This document aims to review the consultation recently carried out to inform the Chrysalis Community Drug Project’s Strategic Plan for the period of 2023-2025. This consultation took place between May-August of 2022, and consisted of three key methods of data collection: 

1. Personal interviews and focus groups (Chrysalis staff, Board of Directors, and management incl. Team Leaders and CEO);
2. External stakeholders questionnaire;
3. Service User focus groups. 

The plan itself is based primarily on data collected from the aforementioned key stakeholders, although relevant academic literature, organisational documents and datasets provided by the Health Research Board heavily inform the nature of qualitative data this consultation aimed to collect, as well as the key themes of the Strategic Plan itself.